Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CASP6 | P55212 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CASP4 | P49662 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | CASP9 | P55211 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16618985 | 0.94 | LMNA (0.52) | LMNACASP6CASP1CASP3CASP4 | |
| SCHEMBL17983441 | 0.91 | LMNA (0.49) | LMNACASP6CASP1CASP3CASP4 | |
| SCHEMBL17983442 | 0.89 | LMNA (0.52) | LMNACASP6CASP1CASP3CASP4 | |
| SCHEMBL15543815 | 0.83 | CASP1 (0.53) | LMNACASP6CASP1CASP3CASP4 | |
| SCHEMBL16618789 | 0.82 | OPRD1 (0.47) | LMNACASP6CASP1CASP3CASP4 | |
| SCHEMBL17983445 | 0.82 | LMNA (0.43) | LMNACASP6CASP1CASP3CASP4 | |
| SCHEMBL31419414 | 0.81 | CASP1 (0.50) | LMNACASP6CASP1CASP3CASP4 | |
| SCHEMBL3592128 | 0.81 | CASP1 (0.50) | LMNACASP6CASP1CASP3CASP4 | |
| SCHEMBL15544539 | 0.81 | CASP1 (0.50) | LMNACASP6CASP1CASP3CASP4 | |
| SCHEMBL1679791 | 0.80 | CASP3 (0.50) | LMNACASP6CASP1CASP3CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-10065926-B2 | Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-09-04 | — | — | US | disclosed |
| US-9949978-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949978-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| EP-3051946-B1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2017-11-29 | — | — | EP | disclosed |
| EP-2847190-B1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | Bayer Pharma AG (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2847190-B1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | Bayer Pharma AG (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| WO-2015049351-A1 | USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AG (DE) | 2015-04-09 | — | — | WO | disclosed |
| EP-2847190-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167495-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-14 | — | — | WO | disclosed |
| EP-1756112-B1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065926-B2 | Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants | SQOR, DHPS, QDPR | LMNA 4818/4885CASP6 3423/4885CASP1 4171/4885 |
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | MKI67, CCNI, CCNA1 | LMNA 2554/4885CASP6 1515/4885CASP1 1075/4885 |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | UNG, UMPS, TYMP | LMNA 2094/4885CASP6 1929/4885CASP1 1846/4885 |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | LMNA 2094/4885CASP6 1929/4885CASP1 1846/4885 |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | LMNA 2094/4885CASP6 1929/4885CASP1 1846/4885 |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | LMNA 2094/4885CASP6 1929/4885CASP1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.